KU Hematology & Medical Oncology Review 2019
Hematologic Malignancies
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - BR vs Ibrutinib & Ibrutinib + Rituximab vs. FCR
FEATURING
Marc Hoffmann
- 386 views
- October 4, 2019
KU Hematology & Medical Oncology Review 2019
KU ASCO 2019: Update on CLL Preferred Therapy - Venetoclax + Obinutuzumab
FEATURING
Marc Hoffmann
- 944 views
- August 19, 2019
- 4